An employer’s perspective: How to navigate the opportunities and risks of GLP-1s

In light of a new and promising class of drugs that could address the entrenched obesity epidemic, HR leaders and plan sponsors are confronted with a host of questions and unknowns regarding how they will address GLP-1s in their strategic benefit plan offering. This may be the most important benefit plan change they will consider this year: How to prioritize employee health while managing pharmacy spend, defining successful outcomes, and having guardrails around who is eligible to be covered.   

Obesity is not a cosmetic concern—it's a serious health issue that requires empathetic and tangible support. It's time to move beyond the traditional boundaries of healthcare benefits and create a supportive, inclusive environment for all employees.  

Tune in to this webinar to learn how to address this pressing issue and foster a culture of health and well-being in our workplaces with the panelists below

• James Wantuck, MD, associate chief medical officer, Accolade & PlushCare
• Nancy Costlow, PharmD, BCSCP, PRS, RPh, sr. director, clinical shared services, Accolade
• Jennifer Hanson, JD, executive vice president, chief human resource officer, Accolade